Enhertu
About Trastuzumab Deruxtecan
Trastuzumab Deruxtecan is prescribed for the treatment of adult patients with metastatic or unresectable HER2-positive breast cancer who have undergone prior anti-HER2-based regimens in the metastatic setting, ENHERTU is a HER2-directed antibody and topoisomerase inhibitor combination.
Strength
100 mg single-dose vial
Recommended Dosage:
Trastuzumab Deruxtecan or Enhertu is to be administered intravenously once every three weeks (a 21-day cycle) until the disease progresses or there is intolerable toxicity. The suggested dosage is 5.4 mg/kg.
Important: If patients experience any adverse reactions from the Trastuzumab, they must consult their treating doctor.
Warnings & Precautions
- Enhertu is to be administered intravenously once every three weeks (a 21-day cycle) until the disease progresses or there is intolerable toxicity (Neutropenia). The recommended dosage is 5.4 mg/kg.
- Before beginning the dosage and during the treatment, it is necessary to evaluate LVEF (Left Ventricular Dysfunction). It is advised to interrupt the treatment or follow discontinuation. Discontinue permanently in patients with congestive heart failure symptoms.
Common Trastuzumab Deruxtecan Side Effects
- Nausea
- Fatigue
- Vomiting
- Alopecia
- Constipation
- Reduced appetite
- Anemia
- Neutropenia
- Diarrhea
- Leukopenia
- Cough
- Thrombocytopenia
Storage and Handling
To protect them from light until reconstitution, keep vials in the original box in the refrigerator between 2ºC to 8ºC. Avoid freezing. Do not shake the diluted or reconstitution solution.
We follow a four-step process to procure the medicines:
- Enquiry about the medicines: You submit a request for information about the medications you require using our portal, and we process your data. Within 24 hours, a member of our Named Access Program Support will get in touch with you and provide you with all the assistance you need.
- Verification Process: As we assist patients in finding medications that are not yet approved and readily available in their home countries, Sansfro must confirm the availability and approval of the medicines they need. We also check the patient’s prescription and medical information.
- Sourcing the Medicine: After the verification process has been successfully completed, our staff will contact our vast network of suppliers to find your medicine. Following the process, our team gets the best rates of the medicines for you and ensures processing.
- Safe Delivery: We will set up the consignment’s safe delivery after the final quote is approved. Additionally, our logistics experts can help you track your consignment. The Named Access Program industry has a large number of unauthorized channels. To provide the medications safely and legally, we do so by adhering to the Standard Operating Procedures.
When importing medication, we will need the following documents from the patient:
- A valid prescription copy.
- An identity proof document.
- Details of the attending healthcare professional.
- A current address.
Once we have all these documents, the Sansfro team will initiate the application process for an import license. This license is essential to ensure that we can obtain the necessary medication once it receives government approval.
No news found.
About Sansfro
Sansfro is committed to bridging the healthcare gap. Our purpose is to bring hope and healing to patients suffering from rare diseases by linking them with life-saving treatments through our Named Patient Program. Join us in our quest for a better and healthier world.
Know More...FAQ'S
How does Trastuzumab Deruxtecan work?
Enherty or Trastuzumab Deruxtecan is a type of targeted therapy known as an antibody-drug conjugate. It works by attaching to the HER2 protein on cancer cells, delivering potent chemotherapy directly to the cancer cell, and blocking the signals that promote cancer cell growth.
Enhertu treats what forms of cancer?
Enhertu or Trastuzumab Deruxtecan has been licensed to treat HER2-positive breast cancer as well as HER2-positive gastric or gastroesophageal junction (GEJ) cancer.
How is Trastuzumab Deruxtecan administered?
A treating doctor administers Enhertu as an intravenous (IV) infusion. He/She will establish the dose and treatment regimen.
What are the potential Enhertu side effects?
Nausea, vomiting, lethargy, decreased appetite, hair loss, and diarrhea are common adverse effects of Enhertu. Interstitial lung disease, cardiac issues, and low blood cell counts are all serious adverse effects.
Is Enhertu appropriate for all patients with HER2-positive cancer??
Enhertu may not be appropriate for all patients. The consulting doctor will review the patient’s medical history and perform the necessary tests to see if Enhertu is appropriate.
What is the price of Enhertu in India?
Enhertu price in India depends on the product requirement. Request more details by reaching out to our Patient Support Team at (+91) 93157 05373 or help@sansfro.com
Dr Anchal Aryan
Medical counselor
Patient Stories
Word Wide Delivery:
India, Andorra, Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe, Afghanistan, Albania, Algeria, American Samoa, Angola, Anguilla, Antarctica, etc.